Lesley Ann Anderson

Lesley Ann Anderson

Auto-generated profile, based on publicly available information

Lesley Ann Anderson

Institute of Applied Health Sciences, University of Aberdeen, Aberdeen, UK

Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2017 in The Lancet Oncology
Verified
Journal Article
Closed access
Gemma GattaGemma Gatta
Gemma Gatta
RCRiccardo Capocaccia
Riccardo Capocaccia
LBLaura Botta
Laura Botta
SMSandra Mallone
Sandra Mallone
RARoberta De Angelis
Roberta De Angelis
EBEllen Benhamou
Ellen Benhamou

1 October 2015 in European Journal of Cancer
Verified
Journal Article
Closed access
Gemma GattaGemma Gatta
Gemma Gatta
LBLaura Botta
Laura Botta
María-José SánchezMaría-José Sánchez
María-José Sánchez
LALesley Ann Anderson
Lesley Ann Anderson
Daniela PierannunzioDaniela Pierannunzio
Daniela Pierannunzio
ROR. Otter
R. Otter

1 December 2012 in Oral Oncology
Verified
Journal Article
Closed access
MOM.A. O’rorke
M.A. O’rorke
MEM.V. Ellison
M.V. Ellison
LML.J. Murray
L.J. Murray
MMM. Moran
M. Moran
JJJ. James
J. James
LAL.A. Anderson
L.A. Anderson

1 August 2014 in The Lancet Oncology
Verified
Journal Article
Closed access
MSMilena Sant
Milena Sant
PMPamela Minicozzi
Pamela Minicozzi
MMMorgane Mounier
Morgane Mounier
LALesley A Anderson
Lesley A Anderson
HBHermann Brenner
Hermann Brenner
RARoberta De Angelis
Roberta De Angelis

3 March 2009 in British Journal of Cancer
Verified
Journal Article
Open access
LAL A Anderson
L A Anderson
RPR M Pfeiffer
R M Pfeiffer
OLO Landgren
O Landgren
SGS Gadalla
S Gadalla
SBS I Berndt
S I Berndt
EEE A Engels
E A Engels
Autoimmune conditions are associated with an elevated risk of lymphoproliferative malignancies, but few studies have investigated the risk of myeloid malignancies. From the US Surveillance Epidemiology and End Results (SEER)-Medicare database, 13 486 myeloid malignancy patients (aged 67+ years) and 160 086 population-based controls were selected. Logistic regression models adjusted for gender, age, race, calendar year and number of physician claims were used to estimate odds ratios (ORs) for myeloid malignancies in relation to autoimmune conditions. Multiple comparisons were controlled for using the Bonferroni correction (P<0.0005). Autoimmune conditions, overall, were associated with an increased risk of acute myeloid leukaemia (AML) (OR 1.29) and myelodysplastic syndrome (MDS, OR 1.50). Specifically, AML was associated with rheumatoid arthritis (OR 1.28), systemic lupus erythematosus (OR 1.92), polymyalgia rheumatica (OR 1.73), autoimmune haemolytic anaemia (OR 3.74), systemic vasculitis (OR 6.23), ulcerative colitis (OR 1.72) and pernicious anaemia (OR 1.57). Myelodysplastic syndrome was associated with rheumatoid arthritis (OR1.52) and pernicious anaemia (OR 2.38). Overall, autoimmune conditions were not associated with chronic myeloid leukaemia (OR 1.09) or chronic myeloproliferative disorders (OR 1.15). Medications used to treat autoimmune conditions, shared genetic predisposition and/or direct infiltration of bone marrow by autoimmune conditions, could explain these excess risks of myeloid malignancies.

22 January 2009 in International Journal of Cancer
Verified
Journal Article
Open access
PDF file
LALesley A. Anderson
Lesley A. Anderson
SGShahinaz Gadalla
Shahinaz Gadalla
LMLindsay M. Morton
Lindsay M. Morton
OLOla Landgren
Ola Landgren
RPRuth Pfeiffer
Ruth Pfeiffer
EEEric A. Engels
Eric A. Engels
Some autoimmune conditions are associated with increased risk of lymphoid malignancies, but information on specific malignancy subtypes is limited. From the U.S. Surveillance Epidemiology and End Results‐Medicare database, we selected 44,350 lymphoid malignancy cases (≥67 years) and 122,531 population‐based controls. Logistic regression was used to derive odds ratios (ORs) comparing the prevalence of autoimmune conditions in cases and controls, by lymphoid malignancy subtype, adjusted for gender, age at malignancy/selection, year of malignancy/selection, race and number of physician claims. The strongest associations observed by non‐Hodgkin lymphoma (NHL) subtypes were diffuse large B‐cell lymphoma with rheumatoid arthritis (OR 1.4, 95%CI 1.2–1.5) and Sjögren syndrome (2.0, 1.5–2.8); T‐cell lymphoma with hemolytic anemia (9.7, 4.3–22), psoriasis (3.1, 2.5–4.0), discoid lupus erythematosus (4.4, 2.3–8.4) and celiac disease (5.0, 2.4–14.); and marginal zone lymphoma with Sjögren syndrome (6.6, 4.6–9.5), systemic lupus erythematosus (2.8, 1.7–4.7) and hemolytic anemia (7.4, 3.1–18). Hodgkin lymphoma was associated with systemic lupus erythematosus (3.5, 1.9–6.7). Multiple myeloma was associated only with pernicious anemia (1.5, 1.3–1.7). Several autoimmune conditions were associated with increased risk of lymphoid neoplasms, especially NHLs of diffuse large B‐cell, marginal zone and T‐cell subtypes. These results support a mechanism whereby chronic antigenic stimulation leads to lymphoid malignancy. Published 2009 UICC.